Evoniks, Solo

Evonik's Solo Story Faces Two Yardsticks: Oddo's 19 Euros and Jefferies' 21

Published on 11/22/2026 at 17:01 | Editorial boerse-global.de
Oddo BHF cut Evonik to Neutral and Jefferies to Hold after BASF dropped its takeover approach; RAG-Stiftung still plans to cut its stake to 25.1%.
Evoniks, Solo, Story, Faces, Two, Yardsticks, Oddos, Euros, Jefferies, Oddo Illustration mit AI erstellt.

Evonik investors now have two fresh analyst markers to weigh against a share price of 18.18 euros — and neither one settles the question of what the chemicals maker is worth on its own. Oddo BHF cut the stock from "Outperform" to "Neutral" on Friday and trimmed its target from 22 euros to 19 euros. Hours earlier in the week, Jefferies had moved from "Buy" to "Hold" while lifting its own target from 20 euros to 21 euros. The pair of moves pull in opposite directions on price but agree on direction of travel: less conviction, not more.

Behind both decisions sits BASF's decision on Thursday to walk away from a takeover of Evonik without entering detailed exploratory talks. Interim chief executive Claus Rettig told Reuters the same day that the withdrawal removes a layer of uncertainty for employees and lets the company concentrate on developing under its own steam. That is a statement about focus, not about future earnings — and the distinction matters for anyone trying to value the equity.

The RAG-Stiftung's plan is unchanged

Evonik's largest shareholder is not altering course either. The RAG-Stiftung confirmed to Reuters on Friday that it still intends to reduce its stake step by step to 25.1%. The foundation also expressed regret that BASF ended its approach without deeper talks. Crucially, the statement describes a target for the holding, not a sale already underway — and it keeps the ownership question separate from the operating one. What will drive the valuation is how much of the expected profit can be sustained into the following year.

BASF, for its part, had considered one more moderate increase but concluded that a higher price would not serve its own shareholders. That leaves the rejected non-binding cash offers — the most recent at 24 euros per share — without any floor-setting role. Evonik turned down both proposals. For the standalone story, the bid price is neither a target nor a lower bound; any return toward that level would have to come from the value of the business itself, not from memory of the sum once on the table.

Should investors sell immediately? Or is it worth buying Evonik?

A confirmed outlook is not a clean bill of health

Evonik supplied its own benchmark on 3 November, specifying that it expects adjusted EBITDA for 2026 in the upper half of a range between 2.0 billion and 2.2 billion euros. That is a yardstick for the current financial year — it says nothing yet about the level the company can hold the year after.

The distinction is where Jefferies' caution bites. The analysis house cut its 2027 EBITDA forecast by 9% to below 2 billion euros, citing fading support from supply disruptions in the Middle East. Should that expectation prove out, even a result in the upper half of Evonik's own guidance would not demonstrate that the earnings level is durable. The market would then have to assess the standalone business against a lower base.

Hitting guidance and a weaker following year would not contradict each other. Investors should not read confirmation of the annual outlook as an all-clear for what comes next.

What would justify a re-rating

The favourable case requires two things at once: Evonik reaching the upper half of its range, and the fading Middle East contribution weighing on the following year by less than Jefferies anticipates. Only that combination would support the idea that Evonik can defend its earnings level without the previous tailwind — and only then would a potential re-rating rest on an operating foundation.

The mirror risk is not merely the absence of a positive catalyst. If earnings prospects deteriorate, investors would have to revise downward their assumptions about what Evonik is worth as an independent company. Until management can point to operating progress that supports better results and explain which improvements are meant to deliver them, headroom for a higher valuation remains largely a scenario.

The 2026 figures are the first real test

The next concrete checkpoint is the 2026 annual results, which can show whether Evonik reached the upper half of its announced range. The further question — whether a good year-end forms the base for stable earnings or whether investors should brace for a weaker foundation — hinges on the company's next earnings outlook. That guidance, more than the gap between the share price and any single analyst target, is what will decide how the standalone case is judged.

Ad

Evonik Stock: New Analysis - 22 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIKS | boerse | 70544625 |